Jamaica's Ministry of Health Approves United Cannabis Corporation's Prana CBD-Infused Water as a Registered Medicinal Cannabi...
October 12 2017 - 8:30AM
Access Wire
The Company's Hemp Aromatherapy Roll-On, Capsules,
and Sublingual Drops Are Already Registered with The Ministry of
Health
DENVER, CO / ACCESSWIRE / October 12, 2017 /
United Cannabis Corporation (OTCQB: CNAB) (the "Company" or "United
Cannabis") today announced that Jamaica's Ministry of Health has
registered its Prana CBD-Infused Water as a medicinal cannabis
product. The Prana Water will be manufactured and distributed by
the Company's Jamaican subsidiary, Cannabinoid Research &
Development Limited ("CRD").
CRD has already begun preliminary work to initiate production of
other United Cannabis products in Jamaica, including its Prana P5
Hemp Bio Nutrient Capsules, Aromatherapy Roll-On, and Sublingual
Drops.
This approval strengthens the Company's competitive advantage by
giving it access to other markets, including Canada, Australia, and
New Zealand, which are approved for the purchase of hemp-based
products from Jamaica.
The Prana Collection is at the center of United Cannabis'
proprietary cannabis-centric therapies and patients have found the
hemp-derived Prana CBD-infused formulations effective in providing
relief from the symptoms of arthritis, neuropathy, acute pain,
joint aches, muscle tension, muscle spasms, muscle recovery,
migraines, and various skin conditions.
Earnest Blackmon, Chief Executive Officer of United Cannabis,
commented on the announcement saying, "Acceptance of medical
cannabis has been considerably faster in Jamaica than the United
States, and we established CRD so that we could be a part of the
commercialization process. Our production facility is
state-of-the-art and we expect our CBD-infused water, as well as
our other approved products, will be ready for distribution by the
end of the month."
About Cannabinoid Research & Development
Limited
Cannabinoid Research & Development (CRD), a subsidiary of
United Cannabis, is a Jamaican based corporation pursuing local
licensing to advance the use of medical cannabis therapies through
biomedical research and development for the nutraceutical industry.
CRD focuses on genetic restoration, cannabinoid isolation
techniques, scientific research, educational programs, and promotes
domestic job opportunities. John Sayers, along with Kenyama Brown,
local Jamaican directors and executives of CRD, coupled with
Jamaican partners specializing in agricultural science and
plant-based medicine, will help United Cannabis implement Sayer's
40 years of agricultural methodologies into localized educational
curriculums, job training programs, and help with integration of
localized products.
About United Cannabis Corporation
United Cannabis Corporation is a biotechnology company dedicated
to the development of phyto-therapeutic based products supported by
patented technologies for the pharmaceutical, medical, and
industrial markets. The Company has long advocated the application
of cannabinoids for medical applications and is building a platform
for designing targeted therapies to increase the quality of life
for patients around the world. The Company's products are patent
protected, first in class medicines with applications to a global
market. United Cannabis trades on the OTCQB under the symbol
CNAB.
For further information, please visit www.unitedcannabis.us.
Contact: Staff@UnitedCannabis.us
Phone: 303-386-7321
Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933, are subject to Rule 3b-6 under the
Securities Exchange Act of 1934, and are subject to the safe
harbors created by those rules. All statements, other than
statements of fact, included in this release, including, without
limitation, statements regarding potential future plans and
objectives of the company, are forward-looking statements that
involve risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and other results and
further events could differ materially from those anticipated in
such statements. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying
the forward-looking statements.
SOURCE: United Cannabis Corporation